KEYNOTE-811: Potential to revise first-line therapy for metastatic human epidermal growth factor receptor 2-positive gastric cancer

Yuwei Ding; Ying Yuan; Shanshan Weng

doi:10.1002/mco2.545

KEYNOTE-811: Potential to revise first-line therapy for metastatic human epidermal growth factor receptor 2-positive gastric cancer

MedComm (2020). 2024 May 7;5(5):e545. doi: 10.1002/mco2.545. eCollection 2024 May.

Authors

Yuwei Ding¹, Ying Yuan^{1

2

3}, Shanshan Weng¹

Affiliations

¹ Department of Medical Oncology (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Key Laboratory of Molecular Biology in Medical Sciences) The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou China.
² Zhejiang Provincial Clinical Research Center for CANCER Hangzhou China.
³ Cancer Center of Zhejiang University Hangzhou China.

Abstract

The first-line therapy pattern transition of metastatic HER2-positive gastric cancer is shifting. The KEYNOTE-811 study demonstrated that the addition of immunotherapy to the standard treatment of HER2-targeted therapy and chemotherapy showed good results in terms of PFS, especially in subgroup patients with PD-L1 CPS≥1. In the future, the first-line therapy pattern of metastatic HER2-positive gastric cancer will be radically changed based on ongoing randomized controlled clinical trials.

Keywords: chemotherapy; gastric cancer; immunotherapy.